Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pigmanorm
- Development stage
- Unknown
- Lead developer
- Louis Widmer
- Modality
- Drug Delivery Systems, Small Molecules
- Administration
- Topical
01
Overview
Pigmanorm is a topical cream medication primarily used to treat melasma, a common skin pigmentation disorder characterized by brown or grey patches that typically develop on the face. It contains three active ingredients that work synergistically to reduce hyperpigmentation: hydroquinone (5%), hydrocortisone (1%), and tretinoin (0.1%).
- Brand names
- PigmanormLouis Widmer Pigmanorm
- Other names
- Pigmason
02
Targets
RARA (Retinoic acid receptor alpha)TYR (Tyrosinase)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on pigmanorm.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pigmanorm.